NasdaqGS:ACADBiotechs
Assessing Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX Rollout And Upcoming Neurology Data Presentations
ACADIA Pharmaceuticals (ACAD) is back in focus after two recent product related updates, including broader U.S. availability of DAYBUE STIX for Rett syndrome and upcoming data presentations across its neurology portfolio at the 2026 AAN meeting.
See our latest analysis for ACADIA Pharmaceuticals.
Recent announcements on broader U.S. availability of DAYBUE STIX and the upcoming neurology data presentations appear to sit behind a 9.10% 1 month share price return. This comes even as the 90 day...